Cover Image
市場調查報告書

全球抗肥胖藥市場

Global Anti-Obesity Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 320547
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
全球抗肥胖藥市場 Global Anti-Obesity Drugs Market 2015-2019
出版日期: 2014年11月26日 內容資訊: 英文 72 Pages
簡介

全球抗肥胖藥市場可區分為末梢作用型抗肥胖藥和中樞作用型抗肥胖藥的2種。該市場預計從2014年到2019年的期間,以39.45%的年複合成長率擴大。

本報告提供全球抗肥胖藥市場相關分析、市場成長展望、市場規模的估計、FDA認證藥及OTC藥物的銷售額收益、各地區的市場形勢與成長展望,及主要供應商簡介等彙整資料,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要產品與服務

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 發病率、罹患率

  • 美國
  • 歐洲

第8章 肥胖的種類

  • 單一遺傳基因肥胖
  • 多遺傳基因肥胖

第9章 肥胖的原因

  • 不健康的飲食習慣
  • 定居性生活方式
  • 特定的藥物
  • 睡眠不足
  • 妊娠
  • 內科的疾病

第10章 肥胖的分類

第11章 市場區隔:各類藥物

  • 末梢作用型抗肥胖藥
  • 中樞作用型抗肥胖藥

第12章 區域區隔

第13章 購買標準

第14章 市場成長的促進要素

  • 肥胖罹患率的增加
  • 定居性生活方式的增加
  • 龐大的未滿足需求
  • 有前途的開發藥物、將銷售的新藥

第15章 成長因素與其影響

第16章 市場課題

  • 高藥物研發成本
  • 不合適的副作用
  • 替代療法
  • 多藥品召回

第17章 成長因素與課題的影響

第18章 市場趨勢

  • 激烈的市場競爭
  • 嚴格法規
  • 策略性聯盟的增加

第19章 趨勢與其影響

第20章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第21章 主要供應商分析

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus

第22章 相關報告

圖表一覽

目錄
Product Code: IRTNTR4645

About Obesity

Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

TechNavio's analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019.

Covered in this Report

The Global Anti-obesity Drugs market can be divided into two segments: Peripherally Acting Anti-obesity Drugs and Centrally Acting Anti-obesity Drugs. This report covers the present scenario and the growth prospects of the Global Anti-obesity Drugs market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of FDA approved drugs and OTC medications used in the treatment of obesity that are available in the market.

TechNavio's report, the Global Anti-obesity Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Anti-obesity Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus

Other Prominent Vendors

  • Amylin
  • Alizyme
  • Boehringer Ingelheim
  • Eisai
  • Merck
  • Norgine
  • Novo Nordisk
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Zafgan

Market Driver

  • Increased Prevalence of Obesity
  • For a full, detailed list, view our report

Market Challenge

  • High Drug Development Costs
  • For a full, detailed list, view our report

Market Trend

  • Stiff Market Competition
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

    • 07.1.1. US
    • 07.1.2. Europe

08. Types of Obesity

  • 08.1. Monogenic Obesity
  • 08.2. Polygenic Obesity

09. Causes of Obesity

  • 09.1. Unhealthy Eating Habits
  • 09.2. Sedentary Lifestyle
  • 09.3. Certain medications
  • 09.4. Lack of Sleep
  • 09.5. Pregnancy
  • 09.6. Medical problems

10. Classification of Obesity

11. Market Segmentation by Drug Class

  • 11.1. Peripherally Acting Anti-obesity Drugs
  • 11.2. Centrally Acting Anti-obesity Drugs

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

  • 14.1. Increase in Prevalence of Obesity
  • 14.2. Increase in Sedentary Lifestyle
  • 14.3. Significant Unmet Needs
  • 14.4. Promising Pipeline and Upcoming Launches of New Drugs

15. Drivers and their Impact

16. Market Challenges

  • 16.1. High Drug Development Costs
  • 16.2. Adverse Side Effects
  • 16.3. Alternative Treatments
  • 16.4. Multiple Drug Recalls

17. Impact of Drivers and Challenges

18. Market Trends

  • 18.1. Fierce Market Competition
  • 18.2. Strict Regulations
  • 18.3. Increase in Strategic Alliances

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Arena Pharmaceuticals
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Geographical Segmentation
    • 21.1.4. Business Strategy
    • 21.1.5. Recent Developments
    • 21.1.6. SWOT Analysis
  • 21.2. F. Hoffmann-La Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Geographical Segmentation by Revenue
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Pipeline Products
    • 21.3.7. Business Strategy
    • 21.3.8. Key Information
    • 21.3.9. SWOT Analysis
  • 21.4. Orexigen Therapeutics
    • 21.4.1. Business Overview
    • 21.4.2. Business Strategy
    • 21.4.3. Recent Developments
    • 21.4.4. SWOT Analysis
  • 21.5. Vivus
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation by Revenue 2013
    • 21.5.4. Business Segmentation by Revenue 2012 and 2013
    • 21.5.5. Geographical Segmentation by Revenue 2013
    • 21.5.6. Business Strategy
    • 21.5.7. Recent Information
    • 21.5.8. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Anti-obesity Drugs Market 2013-2018 (US$ million)
  • Exhibit 3: US Prevalence of Adult Overweight and Obesity (NHANES 2011-2012)
  • Exhibit 4: US Prevalence of Childhood Overweight and Obesity (NHANES 2011-2012)
  • Exhibit 5: Types of Obesity
  • Exhibit 6: Causes of Obesity
  • Exhibit 7: Global Anti-obesity Drugs Market Segmentation by Drug Class
  • Exhibit 8: Global Anti-obesity Drugs Market by Geographical Segmentation 2014
  • Exhibit 9: Arena Pharmaceuticals: Geographical Segmentation
  • Exhibit 10: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 11: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 12: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 13: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 14: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 15: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 16: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 17: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 18: Vivus: Business Segmentation by Revenue 2013
  • Exhibit 19: Vivus: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 20: Vivus: Geographical Segmentation by Revenue 2013
Back to Top